Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Haemonetics Corp (NYSE: HAE) closed the day trading at $64.68 down -0.19% from the previous closing price of $64.80. In other words, the price has decreased by -$0.19 from its previous closing price. On the day, 0.68 million shares were traded. HAE stock price reached its highest trading level at $65.24 during the session, while it also had its lowest trading level at $63.45.
Ratios:
For a better understanding of HAE, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.87. For the most recent quarter (mrq), Quick Ratio is recorded 2.55 and its Current Ratio is at 3.97. In the meantime, Its Debt-to-Equity ratio is 1.35 whereas as Long-Term Debt/Eq ratio is at 1.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on February 07, 2025, Downgraded its rating to Underperform and sets its target price to $68 from $95 previously.
On December 06, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $116.
Raymond James Upgraded its Outperform to Strong Buy on November 08, 2024, while the target price for the stock was maintained at $120.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 11 ’24 when Lingamneni Anila bought 6,238 shares for $90.68 per share.
Strong Stewart W sold 4,312 shares of HAE for $393,039 on Jul 26 ’24. The President, Global Hospital now owns 18,196 shares after completing the transaction at $91.15 per share. On Jul 26 ’24, another insider, Strong Stewart W, who serves as the Officer of the company, bought 4,312 shares for $91.15 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 3255389696 and an Enterprise Value of 4220180224. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.45, and their Forward P/E ratio for the next fiscal year is 13.02. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.37 while its Price-to-Book (P/B) ratio in mrq is 3.58. Its current Enterprise Value per Revenue stands at 3.073 whereas that against EBITDA is 12.195.
Stock Price History:
The Beta on a monthly basis for HAE is 0.40, which has changed by -0.18967676 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, HAE has reached a high of $97.97, while it has fallen to a 52-week low of $58.80. The 50-Day Moving Average of the stock is -5.60%, while the 200-Day Moving Average is calculated to be -17.10%.
Shares Statistics:
Over the past 3-months, HAE traded about 933.34K shares per day on average, while over the past 10 days, HAE traded about 880350 shares per day. A total of 50.24M shares are outstanding, with a floating share count of 49.68M. Insiders hold about 1.11% of the company’s shares, while institutions hold 113.59% stake in the company. Shares short for HAE as of 1740700800 were 6468224 with a Short Ratio of 6.93, compared to 1738281600 on 5242500. Therefore, it implies a Short% of Shares Outstanding of 6468224 and a Short% of Float of 20.36.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
